V 212

Drug Profile

V 212

Alternative Names: Inactivated varicella-zoster vaccine - Merck; V212; Varicella zoster virus vaccine - Merck; VZV vaccine - Merck

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Herpes zoster

Most Recent Events

  • 11 Apr 2017 Merck completes a phase III trial for Herpes zoster (Prevention) in the US, Argentina, Colombia, Ecuador, Puerto Rico, Belgium, Bulgaria, Estonia, India, South Korea, Spain, Germany, Czech Republic, UK, Austria, Slovakia, Lithuania, Greece and Italy (NCT01254630)
  • 24 Feb 2017 Efficacy and adverse events data from a phase III trial in Herpes zoster released by Merck and Co
  • 29 May 2015 No recent reports on development identified - Phase-II for Herpes zoster (Prevention) in Australia, Canada, Denmark and Israel (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top